"Grigore T. Popa" University of Medicine and Pharmacy, Clinical Centre of Diabetes, Nutrition and Metabolic Diseases, "Sf. Spiridon" Clinical Hospital, Iași, Romania.
"Grigore T. Popa" University of Medicine and Pharmacy, Institute of Gastroenterology and Hepatology, "Sf. Spiridon" Clinical Hospital, Iași, Romania.
J Diabetes Res. 2018 Oct 3;2018:1736959. doi: 10.1155/2018/1736959. eCollection 2018.
Gastric emptying and glycemic control pathways are closely interrelated processes. Gastric chyme is transferred into the duodenum with velocities depending on its solid or liquid state, as well as on its caloric and nutritional composition. Once nutrients enter the intestine, the secretion of incretins (hormonal products of intestinal cells) is stimulated. Among incretins, glucagon-like peptide-1 (GLP-1) has multiple glycemic-regulatory effects that include delayed gastric emptying, thus triggering a feedback loop lowering postprandial serum glucose levels. Glycemic values also influence gastric emptying; hyperglycemia slows it down, and hypoglycemia accelerates it, both limiting glycemic fluctuations. Disordered gastric emptying in diabetes mellitus is understood today as a complex pathophysiological condition, with both irreversible and reversible components and high intra- and interindividual variability of time span and clinical features. While limited delays may be useful for reducing postprandial hyperglycemias, severely hindered gastric emptying may be associated with higher glycemic variability and worsened long-term glycemic control. Therapeutic approaches for both gastric emptying and glycemic control include dietary modifications of meal structure or content and drugs acting as GLP-1 receptor agonists. In the foreseeable future, we will probably witness a wider range of dietary interventions and more incretin-based medications used for restoring both gastric emptying and glycemic levels to nearly physiological levels.
胃排空和血糖控制途径是密切相关的过程。胃食糜以其固液状态以及热量和营养成分的不同,以不同的速度转移到十二指肠。一旦营养物质进入肠道,肠细胞分泌的肠促胰岛素(激素产物)就会被刺激。在肠促胰岛素中,胰高血糖素样肽-1(GLP-1)具有多种血糖调节作用,包括延迟胃排空,从而触发降低餐后血清葡萄糖水平的反馈回路。血糖值也会影响胃排空;高血糖会减缓胃排空,低血糖会加速胃排空,这两者都限制了血糖波动。目前认为,糖尿病患者的胃排空障碍是一种复杂的病理生理状况,既有不可逆成分,也有可逆成分,而且个体内和个体间的时间跨度和临床特征的变异性很大。虽然有限的延迟可能有助于降低餐后高血糖,但严重的胃排空障碍可能与更高的血糖变异性和更差的长期血糖控制有关。胃排空和血糖控制的治疗方法包括改变膳食结构或内容的饮食调整以及作为 GLP-1 受体激动剂的药物。在可预见的未来,我们可能会看到更广泛的饮食干预措施和更多基于肠促胰岛素的药物被用于将胃排空和血糖水平恢复到接近生理水平。